PRECLINICAL ASSESSMENT OF BMX/ETK INHIBITORS FOR PROSTATE CANCER

$637,500FY2009Department of the ArmyDOD

Beth Israel Deaconess Medical Center, Inc.

Investigators

View source on USAspending →